Indica Labs Company Overview and Market Research Report
Company Overview
Name: Indica Labs, Inc.
Mission: Transform tissue-based research and diagnostics with computational pathology and AI.
Company Details:
- Founded: 2011
- Founder/CEO: Steven Hashagen
- Headquarters: Albuquerque, New Mexico, USA
- Number of Employees: No information is available
- Revenue: No information is available
- Known for: AI-powered digital pathology software and services
Key People:
- Steven Hashagen, Founder and CEO
- Eric Runde, COO
Products
Indica Labs offers a range of digital pathology products designed to integrate AI and deep learning for various diagnostic and research applications.
HALO® Platform
High-Level Description:
HALO® is a comprehensive image analysis platform designed for tissue-based research applications. It supports quantitative analysis, collaboration, and data management in pathology.
Key Features:
- Quantitative evaluation of whole slide images
- Integration of AI and deep learning algorithms
- Customizable for different research and diagnostic needs
HALO AI®
High-Level Description:
An extension of the HALO platform focusing specifically on AI-powered image analysis.
Key Features:
- Pre-trained tissue classifiers and cell phenotypers
- Customizable and trainable with customer data
- Integration with other HALO modules
HALO AP® and HALO AP Dx
High-Level Description:
Digital pathology platforms for primary diagnosis, suitable for use in clinical and research environments.
Key Features:
- FDA clearance for primary diagnosis (HALO AP Dx)
- CE-IVDR marked for in-vitro diagnostic use
- Facilitates remote work and consultations
HALO Link®
High-Level Description:
A collaborative image management platform designed for research pathology labs.
Key Features:
- Browser-based interface for image sharing and collaboration
- System-wide auditing and compliance features
- Seamless integration with HALO and HALO AI
HALO Clinical AI Solutions
Examples Include:
1. HALO Prostate AI
- CE-IVD certified tool for detection and Gleason grading of prostate cancer.
2. Lung PD-L1 AI
- AI-based tool for scoring PD-L1 IHC in NSCLC.
3. Breast IHC AI
- AI-based decision-support tool for HER2, ER, PR, and Ki67 IHC.
4. Lung Macrodissect AI
- AI-powered tool to streamline tumor annotation and enhance molecular analysis.
Recent Developments
New Product Launches:
1. HALO AI Apps - Pre-trained tissue classifiers and cell phenotypers for life sciences, launched in August 2024.
2. Lung Macrodissect AI - Launched in August 2024 to improve molecular pathology workflows by quantifying tumor content and guiding ROI selection.
3. HALO AP Dx - Received FDA 510(k) clearance in May 2024, enabling primary diagnosis in the US with the Hamamatsu NanoZoomer® S360MD Slide scanner.
Enhanced Features:
- Integration of AI membrane segmentation in the Highplex FL and FISH-IF modules, improving analysis speed and accuracy.
- Development of HALO Link Compliance Add-on to support auditing in research pathology laboratories.
Strategic Partnerships:
1. Paige - Non-exclusive partnership with Paige, integrating Paige’s diagnostic AI models into the HALO AP® platform to enhance pathology workflows (August 2024).
2. Lunit - Agreement for a fully interoperable solution between Indica Labs’ HALO AP® and Lunit’s suite of AI pathology products (April 2023).
Expansion:
- Expanded reseller network in the Asia Pacific region, specifically the Philippines, Thailand, Vietnam, and Malaysia (July 2024).
Industry Recognition and Events:
- Announcement of the Indica Labs’ Bay Area HALO® 2024 User Group Meeting to be held on October 16, 2024.
- Webinar initiatives such as "Introducing HALO AI Apps for the Life Sciences” and “AI-Powered Image Analysis of HCR™ RNA-ISH Assays”.
Compliance and Certifications:
- HALO AP Dx is FDA-cleared in the US.
- HALO AP® and HALO AP Dx have CE-IVDR marking for primary diagnosis in the EU, UK, and Switzerland.
- HALO AP® platform includes built-in compliance with FDA 21 CFR Part 11, HIPAA, and GDPR.
Conclusion
Indica Labs stands out as a leader in AI-driven digital pathology solutions, offering robust platforms for both clinical and research applications. Their commitment to innovation, coupled with strong strategic partnerships and compliance with international standards, positions them as a pivotal player in enhancing diagnostic accuracy and efficiency.